Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction

Starting soon · Not applicable

Conditions studied: Intrauterine Growth Restriction

In brief

The local literature lacks comprehensive information regarding the actual incidence of intrauterine growth restriction (IUGR) and oligohydramnios and currently available therapeutic options. Therefore, the current study was planned with the objective to evaluate the impact of enoxaparin therapy compared with standard management on neonatal outcomes in pregnancies complicated by intrauterine growth restriction (IUGR) with oligohydramnios.

Key facts

Study ID

NCT07462182

Run by

Muhammad Aamir Latif

People needed

108

Starts

2026-04-01

Expected to finish

2026-09-30

Last updated by the study team

2026-03-10

Who can join

Age: 18 and older, up to 40. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Women aged 18-40 years
• Singleton pregnancy
• Gestational age ≥28 weeks (confirmed by first-trimester scan or reliable last menstrual period)
• Diagnosed with both IUGR and oligohydramnios
• Willing to provide informed written consent

You may not qualify if…

• Multiple gestation
• Major fetal congenital anomalies
• Maternal medical disorders affecting pregnancy outcome (e.g., uncontrolled diabetes, chronic hypertension, renal disease)
• Known coagulation disorders or contraindications to enoxaparin
• Women already on anticoagulation therapy.

Where it is running

• Combined Military Hospital — Quetta, Balochistan, Pakistan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.